Whitehawk Therapeutics, Inc (WHWK)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Whitehawk Therapeutics, Inc (WHWK) is up 59.1% since the beginning of the year. At $4 per share, WHWK is trading 29.9% below its 52-week high of $5. Investors who bought $1,000 worth of WHWK shares 5 years ago would now be looking at an investment worth $127.

Whitehawk Therapeutics, Inc (WHWK) has returned 59.09% so far this year and 121.26% over the past 12 months.

Based on dividend-adjusted daily data since Aug 8, 2017, WHWK's average daily return is +0.02%, while the average monthly return is -0.33%.

Historically, 44% of months were positive and 56% were negative. The best month was Jan 2019 with a return of +104.7%, while the worst month was Mar 2019 at -69.9%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.

On a daily basis, WHWK closed higher 45% of trading days. The best single day was Jul 8, 2021 with a return of +63.2%, while the worst single day was Mar 18, 2019 at -71.3%.

Whitehawk Therapeutics, Inc has an annualized alpha of -4.97%, beta of 0.66, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since August 08, 2017.

• This stock participated in 130.20% of S&P 500 Index downside but only -27.35% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.66 may look defensive, but with R2 of 0.02 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

WHWK ranks 88 for risk / return — above 88% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Whitehawk Therapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Whitehawk Therapeutics, Inc was 98.67%, occurring on Jul 2, 2024. The portfolio has not yet recovered.

The current Whitehawk Therapeutics, Inc drawdown is 96.11%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Whitehawk Therapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Whitehawk Therapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.